{"entity":{"id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","aka":[],"tldr":"A phase 1/2 trial of DJI136 in small-cell lung cancer, run by Novartis Pharmaceuticals, now recruiting.","summary":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy is a phase 1/2 interventional study registered as NCT07564401 by Novartis Pharmaceuticals, with 80 participants planned, started 2026-06-16 and due to reach its primary completion in 2031-03-03. Interventions recorded: DJI136. Conditions listed: Extensive-stage Small Cell Lung Cancer (ES-SCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07564401","url":"https://clinicaltrials.gov/study/NCT07564401"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["dji136"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07564401","phase":"1/2","setting":"A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC","sponsor":"Novartis Pharmaceuticals","enrolled":80,"outcomes":[]},"route":"/trials/nct07564401/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"dji136","kind":"drug","name":"DJI136","route":"/drugs/dji136/"}],"company":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}